20th December 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Price reduction makes highly effective MDR Tuberculosis treatment available

Global healthcare major Viatris, MedAccess, and TB Alliance have announced a collaboration to reduce the price of its multidrug-resistant tuberculosis treatment drug ‘Pretomanid’ , by 34%. Globally, only twothirds of the multi-drug resistant TB patients are able to be cured.

Ukraine war didn't have any major impact on pharma trade: Uday Bhaskar

Uday Bhaskar, the director General of the Pharmaceuticals Export Promotion Council of India (Pharmexcil) mentioned that the RussiaUkraine war did not have any significant impact on the Pharma business and that the Indian pharmaceutical industry should focus on complex generics formulations, biopharmaceuticals, and more.

Prejex Inc. partners with Polybond, World Trade Center, Pune for needle-less injections

Prejex Inc. has signed a pact with Polybond, headed by Adit Rathi of Rathi Group, to produce needleless injections. This deal has enabled the shifting of German manufacturing capabilities from Berlin in Germany to Pune in India.

Glenmark Pharma receives final approval from USFDA for generic chest pain capsules

Glenmark Pharmaceuticals announced that they have received final approval from US FDA for Nicardipine Hydrochloride Capsules, 20 mg, and 30 mg. According to the reports, it is the generic version of Cardene Capsules, 20 mg, and 30 mg, by Chiesi USA, Inc.

AstraZeneca drug Imfinzi fails trial as monotherapy for type of Lung Cancer

On Monday, AstraZeneca announced that its drug Imfinzi failed to show positive results for improving overall survival in comparison with platinum-based chemotherapy as a monotherapy treatment of patients with latestage non-small cell lung cancer.

Hyderabad hits bottom of list in precaution dose coverage

The reduced number of COVID-19 cases appears to have put the city of Hyderabad at too much ease, as the district-wise data showed that only 20% of the city’s eligible population opted for the precaution dose, making it remain at the bottom of the list.

Atara establishes miltestone with world's first approval for allogenic T-cell therapy

Atara Biotherapeutics company announced that its allogeneic Epstein-Barr virus-positive (EBV) T-cell therapy tabelecleucel has received the world-first approval in Europe. Atara’s drug collects T-cells from healthy donors, unlike other autologous cell therapies in the market.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?